Supplementary Figure S1. Src promotes SW620 cell growth in nude mice.
Xenograft tumour growth in nude mice of SW620 cells that were infected with indicated virus. Top panel: time-course of tumour volume from cells infected with mock (square) and Src expressing viruses (triangle). Bottom panel: tumour mass 24 days post-injection. Is shown the mean ± SEM (n = 8)
Supplementary Figure S2. Src increases and activates a cluster of TyrK in SW620 cells in the absence of orthovanadate.

A. Src increases the phosphorylation of a cluster of TyrK in SW620 cells in the absence of orthovanadate treatment.

B. Src induces an increase in Syk and Met activities in SW620 cells in absence of orthovanadate treatment.

C. Src increases the phosphorylation of non-TyrK substrates in the absence of orthovanadate treatment.
Supplementary Figure S3. Tyrosine kinases targeted by Src are not required for its proliferative activity in SW620-Src cells.

A. Growth (arbitrary units) in standard conditions of SW620-Src cells infected with viruses encoding control shRNA (mock) or shRNA specific to indicated tyrosine kinase.

B. SW620-Src cell growth in the presence of DMSO or 5 μM SU6656, 2 μM SU11274 or 5 μM BAY 61-3606 as indicated.
Supplementary Figure S4. Tyrosine kinases targeted by Src are required for cellular invasiveness.

A. Level of shown TyrK in SW620 expressing indicated shRNA

B. Invasive activity of SW620 expressing s indicated shRNA

C. Level of shown TyrK in SW620-Src transfected with indicated siRNA.

D. Invasive activity of SW620-Src cells transfected with indicated siRNA.